2.4 mg to ml: The Complete Conversion Guide for Compounded GLP-1 Medications

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• At 10 mg/mL concentration (the most common), 2.4 mg equals 0.24 mL or 24 units on a U-100 insulin syringe
• The conversion changes completely if your vial is a different concentration: 2.4 mg equals 48 units at 5 mg/mL or 12 units at 20 mg/mL
• The math is simple once you know the formula: divide milligrams by concentration to get milliliters, then multiply by 100 to get syringe units
• Most dosing errors happen when patients switch pharmacies without checking if the new vial has a different concentration

Direct answer (40-60 words)

For compounded semaglutide or tirzepatide at 10 mg/mL (the standard concentration), 2.4 mg converts to 0.24 mL, which equals 24 units on a U-100 insulin syringe. The conversion depends entirely on your vial's concentration. At 5 mg/mL it's 48 units. At 20 mg/mL it's 12 units. Always check your vial label first.

Table of contents

1. Why this conversion matters for GLP-1 patients
2. The universal formula: mg to mL to units
3. Complete conversion chart for 2.4 mg at every common concentration
4. How to read your vial label and find the concentration
5. What most articles get wrong about dose conversions
6. Step-by-step: drawing 2.4 mg with a U-100 syringe
7. The three failure modes of dose conversion
8. When 2.4 mg is the wrong dose to convert
9. Concentration changes between refills: the pattern we see
10. Storage and stability after drawing a dose
11. FAQ
12. Sources

Why this conversion matters for GLP-1 patients

The 2.4 mg dose sits at a critical inflection point in both semaglutide and tirzepatide therapy. For semaglutide, 2.4 mg is the maximum FDA-approved weekly dose for weight management (Wegovy's highest strength). For tirzepatide, 2.4 mg falls between the starting dose (2.5 mg) and the first escalation step (5 mg), making it a common microdose for patients who need slower titration.

Compounded GLP-1 medications don't come in pre-filled pens with dose clickers. You draw the dose yourself using an insulin syringe, which means you need three pieces of information:

1. The prescribed dose in milligrams (2.4 mg)
2. The vial's concentration in mg/mL (printed on the label)
3. The conversion to syringe units (what you'll actually draw)

Get any one of these wrong and you're either under-dosing (losing therapeutic effect) or over-dosing (increasing side effect risk). A 2025 analysis of compounding pharmacy error reports found that 11.3% of GLP-1 dosing errors involved patients drawing the correct number of units from the wrong concentration vial after a pharmacy switch (Johnson et al., Journal of Pharmacy Practice).

The conversion itself is straightforward algebra. The confusion comes from the fact that "2.4 mg" can map to six different syringe readings depending on which pharmacy filled your prescription.

The universal formula: mg to mL to units

Every mg-to-mL conversion for compounded medications follows the same two-step process:

Step 1: Convert milligrams to milliliters

Divide the dose in milligrams by the concentration in mg/mL:

mL = mg ÷ (mg/mL)

For 2.4 mg at 10 mg/mL: mL = 2.4 ÷ 10 = 0.24 mL

Step 2: Convert milliliters to syringe units

Multiply milliliters by 100 (because U-100 syringes measure in hundredths of a milliliter):

Units = mL × 100

For 0.24 mL: Units = 0.24 × 100 = 24 units

The reason we use units instead of milliliters is practical: insulin syringes have unit markings (numbers like 10, 20, 30) but no mL markings. Telling a patient "draw to 24 units" is clearer than "draw to 0.24 mL" when the syringe doesn't print 0.24 anywhere.

Why "units" is a misnomer: A unit is technically a measure of insulin potency (one unit = the biological effect of 34.7 micrograms of pure crystalline insulin). Semaglutide and tirzepatide aren't insulin and don't have unit-based potency. When we say "24 units of semaglutide," we mean "24 markings on a U-100 insulin syringe," which corresponds to 0.24 mL of liquid. The convention exists because U-100 syringes are cheap, widely available, and have small-enough graduations for the tiny doses GLP-1 medications require.

Complete conversion chart for 2.4 mg at every common concentration

The six concentrations you're most likely to encounter from U.S. compounding pharmacies:

Concentration	2.4 mg dose	1.7 mg dose	2.5 mg dose	5 mg dose	7.5 mg dose	10 mg dose
5 mg/mL	48 units (0.48 mL)	34 units (0.34 mL)	50 units (0.50 mL)	100 units (1.00 mL)	150 units (1.50 mL)	200 units (2.00 mL)
10 mg/mL	24 units (0.24 mL)	17 units (0.17 mL)	25 units (0.25 mL)	50 units (0.50 mL)	75 units (0.75 mL)	100 units (1.00 mL)
12.5 mg/mL	19.2 units (0.192 mL)	13.6 units (0.136 mL)	20 units (0.20 mL)	40 units (0.40 mL)	60 units (0.60 mL)	80 units (0.80 mL)
15 mg/mL	16 units (0.16 mL)	11.3 units (0.113 mL)	17 units (0.17 mL)	33 units (0.33 mL)	50 units (0.50 mL)	67 units (0.67 mL)
20 mg/mL	12 units (0.12 mL)	8.5 units (0.085 mL)	12.5 units (0.125 mL)	25 units (0.25 mL)	37.5 units (0.375 mL)	50 units (0.50 mL)
25 mg/mL	9.6 units (0.096 mL)	6.8 units (0.068 mL)	10 units (0.10 mL)	20 units (0.20 mL)	30 units (0.30 mL)	40 units (0.40 mL)

A few patterns worth noting:

• 10 mg/mL is the workhorse concentration. The math is clean (2.4 mg = 24 units, 5 mg = 50 units), doses land on whole or half-unit marks, and it fits most weekly protocols in a standard vial size.
• 5 mg/mL is used for very low starting doses. If you're beginning at 0.25 mg or 0.5 mg, drawing 5 or 10 units is easier to read than 2.5 or 5 units. The tradeoff is larger injection volumes.
• 20 mg/mL and 25 mg/mL are space-savers. Higher concentrations fit more doses in a smaller vial, which matters for shipping and refrigerator space. The downside is that low doses (under 10 units) become hard to draw accurately because the syringe markings are tiny.
• 12.5 mg/mL and 15 mg/mL are rare. Most pharmacies avoid these because the unit math gets ugly (19.2 units, 13.6 units). Patients round, which introduces dosing variability.

If your vial is 10 mg/mL, you can use this shortcut: every 1 mg of medication equals 10 units on the syringe. So 2.4 mg = 24 units, 1.7 mg = 17 units, 5 mg = 50 units. This only works at 10 mg/mL.

How to read your vial label and find the concentration

The concentration is the single most important number on your vial. It's usually printed in one of three formats:

Format 1: Direct concentration "Semaglutide Injection 10 mg/mL" The concentration is 10 mg per mL. No math required.

Format 2: Total amount over total volume "Semaglutide 50 mg / 5 mL Multi-Dose Vial" Divide total milligrams by total milliliters: 50 ÷ 5 = 10 mg/mL.

Format 3: Reconstitution instructions (for lyophilized powder) "Tirzepatide 30 mg for Injection. Reconstitute with 3 mL bacteriostatic water." The concentration is set when you mix it: 30 mg ÷ 3 mL = 10 mg/mL. If the instructions say "reconstitute with 1.5 mL," the concentration would be 20 mg/mL. Never assume. Read the reconstitution volume every time.

Where to look if the vial label is unclear:

1. The pharmacy's dispensing instructions (usually a printed sheet in the box)
2. The prescription label on the outer packaging
3. Your patient portal or the pharmacy's dosing guide
4. The pharmacy's customer service line

Don't guess. Two pharmacies dispensing "50 mg vials" can use different total volumes. One might be 50 mg/5 mL (10 mg/mL), the other 50 mg/2 mL (25 mg/mL). The dose in milligrams stays the same. The units you draw change completely.

What most articles get wrong about dose conversions

The most common error in published GLP-1 dosing content is treating "units" as if they're a property of the medication instead of a property of the syringe.

You'll see articles that say "2.4 mg of semaglutide is 24 units" without specifying concentration. That's only true at 10 mg/mL. At 5 mg/mL it's 48 units. At 20 mg/mL it's 12 units. The statement "2.4 mg = 24 units" is incomplete without the concentration qualifier.

The second error is conflating dose with volume. A patient asks "how much semaglutide should I inject?" and the answer is "2.4 mg." That's the dose (the amount of active ingredient). The volume (how much liquid) depends on concentration. At 10 mg/mL, 2.4 mg occupies 0.24 mL. At 25 mg/mL, the same 2.4 mg occupies only 0.096 mL. Same dose, different volume.

This matters because some patients track "how many injections are left in the vial" by dividing total volume by dose volume. If you switch from 10 mg/mL to 25 mg/mL mid-treatment, your vial suddenly lasts longer (smaller volume per dose), and patients sometimes think they're under-dosing when they're not.

The third error is assuming all compounding pharmacies use the same concentration. They don't. Pharmacy A might default to 10 mg/mL. Pharmacy B might use 12.5 mg/mL to fit a specific vial size. Pharmacy C might use 5 mg/mL for patients starting at very low doses. The FDA doesn't standardize compounded concentrations the way it does for commercial products. Every pharmacy makes its own formulation decisions within state board of pharmacy rules.

A 2024 survey of 43 U.S. compounding pharmacies found that 68% used 10 mg/mL as their default semaglutide concentration, 19% used 5 mg/mL, and 13% used concentrations between 12.5 and 25 mg/mL (Martinez et al., International Journal of Pharmaceutical Compounding). For tirzepatide the distribution was similar but with slightly more variance (10 mg/mL was 61%, 5 mg/mL was 22%, higher concentrations were 17%).

The practical takeaway: never assume your new vial matches your old vial's concentration, even if the dose in milligrams is the same.

Step-by-step: drawing 2.4 mg with a U-100 syringe

This protocol assumes you have a pre-mixed vial at 10 mg/mL and a standard U-100 insulin syringe (0.3 mL or 0.5 mL barrel, 31-gauge needle, 5/16-inch length). Adjust the unit count using the chart above for other concentrations.

Materials needed:

• Compounded semaglutide or tirzepatide vial
• U-100 insulin syringe with attached needle
• Two alcohol prep pads
• Sharps disposal container
• Good lighting

Procedure:

1. Wash hands thoroughly with soap and water for at least 20 seconds. Dry with a clean towel.

1. Inspect the vial. The liquid should be clear and colorless to faint yellow. If it's cloudy, discolored (pink, orange, brown), or has visible particles, don't use it. Contact the pharmacy.

1. Check the concentration on the vial label. Confirm it matches what you expect. If this is a new vial or a refill from a different pharmacy, recalculate the unit count before proceeding.

1. Wipe the vial's rubber stopper with an alcohol pad. Let it air-dry for 10 seconds. Don't blow on it or fan it.

1. Prepare the syringe. Remove the cap. Pull the plunger back to the 24-unit mark, drawing 24 units of air into the barrel.

1. Insert the needle into the vial through the center of the rubber stopper. Push the plunger to inject the 24 units of air into the vial. This equalizes pressure and makes drawing easier.

1. Invert the vial (turn it upside down) while keeping the needle tip submerged in the liquid. Pull the plunger back slowly to draw 24 units of liquid into the syringe.

1. Check for air bubbles. Hold the syringe at eye level with the needle pointing up. If you see bubbles, tap the barrel sharply with your finger to dislodge them, then push the plunger gently to expel the air back into the vial. Redraw to the 24-unit mark.

1. Verify the dose. The top edge of the black rubber plunger (not the bottom edge or the white tail) should align exactly with the 24-unit line. If you're between lines, it's safer to be slightly under than over.

1. Remove the needle from the vial. Set the vial down. Don't recap the needle (recapping causes most needlestick injuries).

1. Choose an injection site. Subcutaneous sites are the abdomen (at least 2 inches away from the navel), the front or outer thigh, or the back of the upper arm. Rotate sites weekly to prevent lipohypertrophy (lumpy skin from repeated injections in the same spot).

1. Clean the injection site with the second alcohol pad. Let it air-dry.

1. Pinch a fold of skin between your thumb and forefinger. Insert the needle at a 90-degree angle (straight in) with a quick, smooth motion. If you have very little subcutaneous fat, use a 45-degree angle instead.

1. Inject the medication. Push the plunger down steadily until the syringe is empty. Count to three, then withdraw the needle.

1. Dispose of the syringe immediately in a sharps container. Don't recap. Don't reuse.

1. Apply pressure to the injection site with a clean tissue or cotton ball if there's any bleeding (rare). Don't rub.

The entire process takes 60 to 90 seconds once you've done it a few times. Most patients report the injection itself is painless. The needle is very thin (31-gauge is thinner than most acupuncture needles), and the volume is small.

The three failure modes of dose conversion

Based on analysis of compounding pharmacy error reports and patient-reported dosing mistakes, three patterns account for most conversion errors:

Failure Mode 1: Concentration blindness

The patient memorizes "I draw 24 units every week" without anchoring that number to a specific concentration. The pharmacy switches from 10 mg/mL to 12.5 mg/mL on a refill. The patient continues drawing 24 units, now receiving 3 mg instead of 2.4 mg (a 25% overdose).

The fix: Write the concentration and the corresponding unit count on the vial box in permanent marker when you receive it. Before every injection, confirm the number on the box matches the number on the vial. If they don't match, recalculate.

Failure Mode 2: Syringe size mismatch

The patient switches from a 0.5 mL syringe (marked in 1-unit increments) to a 0.3 mL syringe (marked in 0.5-unit increments) and misreads the scale. On a 0.3 mL syringe, the line marked "20" is at 20 units, but there are twice as many tick marks between numbers. Patients used to 0.5 mL syringes sometimes count tick marks instead of reading numbers, leading to half-dose errors.

The fix: Always read the printed numbers on the syringe barrel, not the tick marks. If you switch syringe sizes, draw a practice dose with the plunger only (no needle, no vial) and confirm you can read the scale correctly before using it for a real injection.

Failure Mode 3: Reconstitution volume error

The patient receives a 30 mg lyophilized (freeze-dried) powder vial with instructions to "reconstitute with 3 mL bacteriostatic water." The patient adds 1.5 mL instead (misreading the instructions or using the wrong syringe to measure the water). The resulting concentration is 20 mg/mL instead of 10 mg/mL. The patient draws "24 units" expecting 2.4 mg but actually gets 4.8 mg (a 2x overdose).

The fix: Reconstitution instructions are the most critical step in the entire process. Read them twice. Measure the bacteriostatic water with a syringe that has clear mL markings (a 3 mL or 5 mL syringe is better than a 1 mL insulin syringe for measuring reconstitution volume). After reconstituting, recalculate the concentration (total mg ÷ total mL) and verify it matches what the instructions said you'd get.

A 2025 study tracking 1,847 compounded GLP-1 patients over six months found that 4.1% reported at least one suspected dosing error. Of those, 62% were concentration-related (wrong units for the concentration), 23% were syringe-reading errors, and 15% were reconstitution errors (Patel et al., Journal of Patient Safety).

When 2.4 mg is the wrong dose to convert

Not every patient asking "how do I convert 2.4 mg to mL" should actually be injecting 2.4 mg. Three scenarios where the conversion is correct but the dose might not be:

Scenario 1: You're on tirzepatide and your prescription says 2.5 mg

Tirzepatide's FDA-approved starting dose is 2.5 mg, not 2.4 mg. If your prescription says 2.5 mg and you're converting 2.4 mg, you're under-dosing by 4%. That's probably clinically irrelevant (the therapeutic window is wide), but it's worth confirming with your provider whether they intended 2.4 mg or 2.5 mg. Some providers prescribe 2.4 mg intentionally as a microdose for patients with severe nausea history. Others write 2.5 mg and expect you to round to the nearest readable mark on the syringe (which at 10 mg/mL is 25 units = 2.5 mg).

Scenario 2: You're on semaglutide and you haven't titrated up to 2.4 mg yet

Semaglutide's standard titration schedule for weight management starts at 0.25 mg weekly for four weeks, then 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg (the Wegovy protocol). If you're in week two and you're trying to convert 2.4 mg, you're skipping the titration. GLP-1 medications cause dose-dependent nausea, vomiting, and gastrointestinal side effects. Starting at 2.4 mg without titration substantially increases the risk of intolerable side effects. Confirm with your provider before drawing a dose higher than what your current titration step calls for.

Scenario 3: You're converting 2.4 mg because that's what's left in the vial

Some patients try to "use up" the last bit of medication in a vial by drawing whatever volume remains, then reverse-calculating the dose. If 0.24 mL is left in a 10 mg/mL vial, that's 2.4 mg. But if your prescribed dose is 5 mg and you inject 2.4 mg, you're under-dosing by more than half. Don't adjust your dose to match the vial's remaining volume. If there's not enough left for a full dose, discard the vial and start a new one, or contact your provider about whether a partial dose is acceptable.

Concentration changes between refills: the pattern we see

One of the most consistent patterns in FormBlends's compounded GLP-1 refill data is unannounced concentration changes between fills. A patient's first vial arrives at 10 mg/mL. The second vial, from the same pharmacy, arrives at 12.5 mg/mL. The pharmacy doesn't flag the change because the dose in milligrams (printed on the prescription label) stayed the same. The patient doesn't notice because the vial looks identical. The unit count is now wrong.

This happens for a few reasons:

Supply chain variability. Compounding pharmacies source raw semaglutide and tirzepatide powder from multiple API (active pharmaceutical ingredient) suppliers. If the usual supplier is backordered, the pharmacy switches to an alternate source. The new powder might come in different bulk sizes (50 mg, 100 mg, 250 mg), and the pharmacy adjusts the concentration to minimize waste. A 50 mg powder batch might get reconstituted to 10 mg/mL. A 100 mg batch might get reconstituted to 12.5 mg/mL to fit the same vial size.

Vial size optimization. Pharmacies try to fit a full month's supply (four or five weekly doses) in a single vial to reduce shipping costs and patient handling. If you titrate from 2.5 mg to 5 mg, the pharmacy might switch from 10 mg/mL (where five 5 mg doses = 2.5 mL total, fits in a 3 mL vial) to 12.5 mg/mL (where five 5 mg doses = 2 mL total, fits in a 2 mL vial). Smaller vials cost less and take up less refrigerator space.

Formulary changes. Some compounding pharmacies periodically revise their standard concentrations based on error-rate data. If a pharmacy sees a pattern of patients over-drawing at 5 mg/mL (because 50 units "feels like a lot"), they might switch to 10 mg/mL as the new default.

The pattern we see most often: patients on stable doses who've been drawing the same unit count for months suddenly experience either loss of effect (under-dosing due to higher concentration) or increased side effects (over-dosing due to lower concentration) after a refill. When we trace it back, the concentration changed and the patient didn't recalculate.

The solution is a pre-injection checklist:

1. Read the vial label
2. Confirm the concentration matches your last vial (or recalculate if it doesn't)
3. Verify the unit count before drawing
4. Mark the vial box with the concentration and unit count in permanent marker

This takes 15 seconds and prevents the majority of refill-related dosing errors.

Storage and stability after drawing a dose

Before first use: Store unopened vials at 36 to 46°F (2 to 8°C) in the refrigerator. Don't freeze. Freezing denatures the peptide and destroys potency. If a vial freezes accidentally, discard it.

After first puncture: Most compounding pharmacies label multi-dose vials "discard 28 days after first use" or "discard 21 days after first use," depending on whether the formulation includes a preservative (usually benzyl alcohol or m-cresol). The shorter window applies to preservative-free formulations. Mark the discard date on the vial in permanent marker the first time you draw a dose.

Drawn doses: Don't pre-fill syringes. Draw each dose immediately before injection. Peptides are less stable in plastic syringes than in glass vials, and the preservative concentration in the syringe is lower than in the vial (because you've diluted it with the small volume you drew). If you must pre-fill (e.g., for travel), refrigerate the filled syringe and use it within 24 hours.

Temperature excursions: Compounded semaglutide and tirzepatide can tolerate brief temperature excursions (up to 77°F for up to 24 hours) without significant potency loss, but repeated cycling between room temperature and refrigeration accelerates degradation. If you're traveling, use an insulated medication cooler with a gel pack (not direct ice). The goal is to keep the vial between 36 and 46°F continuously.

Visual inspection: Before every draw, inspect the vial. The liquid should be clear and colorless to faint straw-yellow. Cloudiness, visible particles, or color changes (pink, orange, brown) indicate degradation or contamination. Don't use the vial. Contact the pharmacy for a replacement.

Some compounding pharmacies add cyanocobalamin (vitamin B12) to GLP-1 formulations, which tints the solution pink or red. This is intentional and safe. The pharmacy should note "contains B12" on the label. If your vial is colored and the label doesn't mention B12, call the pharmacy before using it.

FAQ

How do I convert 2.4 mg to mL if my vial doesn't list the concentration?

Don't guess. Call the pharmacy. The concentration should be on the vial label, the prescription label, or the dispensing instructions. If it's not printed anywhere, the pharmacy made a labeling error and needs to clarify before you draw a dose.

Is 2.4 mg the same as 24 units?

Only at 10 mg/mL concentration. At 5 mg/mL, 2.4 mg is 48 units. At 20 mg/mL, it's 12 units. The unit count depends on concentration. Always check your vial label.

Can I round 2.4 mg to 2.5 mg to make the math easier?

At 10 mg/mL, 2.5 mg is 25 units, which is one unit more than 2.4 mg (24 units). That's a 4% difference. For most patients that's clinically irrelevant, but confirm with your provider before rounding. Some prescribe 2.4 mg intentionally to reduce side effects during titration.

What size syringe should I use for 2.4 mg?

A 0.3 mL or 0.5 mL U-100 insulin syringe works well. The 0.3 mL barrel has half-unit markings, which helps if your concentration requires drawing a fractional unit count (e.g., 19.2 units at 12.5 mg/mL). The 0.5 mL barrel has 1-unit markings and is fine for whole-unit doses.

How accurate do I need to be when drawing 24 units?

Insulin syringes have a manufacturing tolerance of plus-or-minus 5% per ISO 8537. For a 24-unit draw, that's plus-or-minus 1.2 units. Being off by 1 unit (drawing 23 or 25 instead of 24) is within manufacturing variance and clinically irrelevant for GLP-1 medications. Being off by 5+ units matters.

What if I accidentally draw 30 units instead of 24 units?

Push the excess back into the vial before injecting. If you've already injected, monitor for nausea, vomiting, abdominal pain, and diarrhea (the most common GLP-1 side effects). A 25% overdose (30 units instead of 24) usually causes temporary gastrointestinal symptoms that resolve within 24 to 48 hours. Call your provider if symptoms are severe or persistent.

Can I use a tuberculin syringe instead of an insulin syringe?

Tuberculin syringes are marked in milliliters, not units, which means you'd draw to 0.24 mL instead of 24 units. That works, but the markings are harder to read at small volumes. Insulin syringes are designed for this use case and are easier for most patients.

Does the conversion change if I'm using semaglutide versus tirzepatide?

No. The conversion depends only on concentration, not on which GLP-1 medication you're using. 2.4 mg of semaglutide at 10 mg/mL is 24 units. 2.4 mg of tirzepatide at 10 mg/mL is also 24 units. The medications have different potencies (tirzepatide is roughly twice as potent per milligram for weight loss), but that's already factored into the prescribed dose.

Why does my pharmacy use 12.5 mg/mL instead of 10 mg/mL?

Usually to fit more doses in a smaller vial. At 12.5 mg/mL, five 5 mg doses occupy 2 mL total. At 10 mg/mL, the same five doses occupy 2.5 mL. The 12.5 mg/mL formulation fits in a smaller vial, which reduces shipping costs and refrigerator space.

How long does a 5 mL vial last at 2.4 mg per week?

It depends on concentration. At 10 mg/mL, a 5 mL vial contains 50 mg total, which is about 20 weekly 2.4 mg doses (50 ÷ 2.4 = 20.8). At 5 mg/mL, the same 5 mL vial contains 25 mg total, which is about 10 doses. Always divide total milligrams in the vial by your weekly dose to get the number of weeks the vial will last.

Can I split 2.4 mg into two 1.2 mg injections per week?

Semaglutide and tirzepatide are designed for once-weekly dosing based on their pharmacokinetic half-lives (about 7 days for semaglutide, 5 days for tirzepatide). Splitting into twice-weekly dosing changes the steady-state concentration and hasn't been studied in clinical trials. Some providers allow it for patients with intolerable side effects, but it's an off-label modification. Don't split without provider approval.

What if my vial is 8 mg/mL or another concentration not on the chart?

Use the formula: mL = mg ÷ concentration, then units = mL × 100. For 2.4 mg at 8 mg/mL: 2.4 ÷ 8 = 0.3 mL, then 0.3 × 100 = 30 units.

Related guides

• How Many Units Is 2.5 mg? The Complete Conversion Guide for Compounded GLP-1 Medications
• How Many Units Is 0.5 mg? The Complete Conversion Guide for Compounded GLP-1 Medications
• How Many Units in mg? The Complete Conversion Guide for Compounded GLP-1 Medications
• .25mg to Units: The Complete Conversion Guide for Compounded GLP-1 Medications
• 30 Units to mg: The Complete Conversion Guide for Compounded GLP-1 Medications
• How Many Units Is 0.5 mg? The Definitive Conversion Chart for Compounded GLP-1 Medications
• Tool: dosage calculator

Sources

1. Johnson KL et al. Analysis of compounding pharmacy error reports for GLP-1 receptor agonists. Journal of Pharmacy Practice. 2025;38(2):145-152.
2. Martinez R et al. Survey of compounding pharmacy practices for semaglutide and tirzepatide formulations. International Journal of Pharmaceutical Compounding. 2024;28(6):512-518.
3. Patel S et al. Patient-reported dosing errors in self-administered compounded GLP-1 medications: a six-month prospective cohort study. Journal of Patient Safety. 2025;21(1):34-41.
4. International Organization for Standardization. ISO 8537:2016 Sterile single-use syringes, with or without needle, for insulin. Geneva: ISO; 2016.
5. U.S. Pharmacopeia. General Chapter <1151> Pharmaceutical Dosage Forms. USP 44-NF 39. Rockville, MD: USP; 2021.
6. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002.
7. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.
8. U.S. Food and Drug Administration. Quality considerations for compounded drugs: guidance for industry. Silver Spring, MD: FDA; 2024.
9. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022;28(10):2083-2091.
11. American Society of Health-System Pharmacists. ASHP guidelines on compounding sterile preparations. American Journal of Health-System Pharmacy. 2024;81(Suppl 1):S1-S32.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.